Early clinical · first deals Has released Phase 1 results for two targeted cancer candidates and widened the VRN11 trial to four countries. Also seen: Global approvals · expansion
Received Malaysian approval for the global Phase 1b/2 trial of VRN11. Source
Presented VRN11 Phase 1 results at ESMO 2026. Source
Roles often seen at this stageClinical & PV · Research & development · Regulatory affairs
A drug developer that uses its VORONOMICS platform to discover kinase inhibitors designed to reach the brain.
01
Products & pipeline
VRN11
Phase 1
A candidate for EGFR-mutant non-small cell lung cancer; in Phase 1, seven of eight C797S-mutant patients dosed at 160 mg or more had an objective response, and a global Phase 1b/2 trial runs in Australia, Hong Kong, Singapore and Malaysia.
VRN10
Phase 1
A HER2-targeted cancer candidate whose Phase 1 results were presented at ESMO 2026.
VORONOMICS
Technology platform
Its in-house discovery platform for quickly finding selective, brain-penetrant development candidates.
02
Recent developments
Completion reported
Received Malaysian approval for the global Phase 1b/2 trial of VRN11, bringing the trial to four countries.
Completion reported
Presented Phase 1 results for VRN11 and VRN10 at ESMO 2026.
03
Experience in official career sources
Official role guide
Voronoi careers
Current availability unconfirmed
Observed 2026-11-18
Work
Unconfirmed — The official careers page was found, but postings and duties were not read in this check.
Experience & requirements
Unconfirmed — Requirements were not checked on the official careers page.
Information from a role guide does not establish a current vacancy.
Sources & coverage 5
A brief based on selected official material, not an exhaustive product or vacancy list.
Voronoi ↗보로노이 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable